Specifically on atopic dermatitis, and the prescribing of appropriate emollients, the relevant doctor or healthcare professional is responsible for working with their patient and deciding on the best course of treatment. Prescribers take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards when making decisions. The National Institute for Health and Care Excellence (NICE) also publishes a range of guidance on atopic dermatitis and other skin conditions for commissioners and healthcare professionals, with recommendations for diagnosis and referral, which are available at the NICE website.

On dermatology care in general, waiting times, and the proposal for a national service framework, I refer the Noble Baroness to the answer that I provided her on 13 January in response to Question HL13259, which, for ease of reference, is reproduced below:

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. The Government will consider clinical specialities for future waves of modern service frameworks, including allergy, dermatology, which includes chronic spontaneous urticaria (CSU), and immunology. The criteria for determining other conditions for future modern service frameworks will be based on disease burden, care variation, economic impact, and where there is potential for rapid and significant improvements in the quality of care and productivity.

The Department recognises the potential benefits of virtual clinics in improving access to specialist care for conditions like CSU. A central part of our 10-Year Health Plan is moving care closer to home, and we recognise that we need to do this while retaining access to specialist support. Trusts should provide the infrastructure and resources to facilitate virtual consultations, but this should not replace face-to-face care where it is more appropriate, dependent on clinical need, or preferred by individual patients.

NHS England’s service specification for specialised dermatology services for adults and children is designed to reduce regional disparities in care for CSU by setting consistent national standards for diagnosis, treatment, and follow-up. The specification ensures that all patients, regardless of location, have access to evidence-based interventions and specialist expertise, including advanced therapies where clinically appropriate. The specification addresses historical variations in service provision and supports equitable access across integrated care systems. This approach helps to improve outcomes for patients with CSU and ensures a more uniform level of care throughout England.

Additionally, NHS England’s Getting It Right First Time programme is working to improve capacity and waiting times through its established Further Faster programme. This programme brings together hospital trust clinicians and operational teams with the challenge of collectively going ‘further and faster’ to transform patient pathways, reduce unnecessary follow-up outpatient appointments, and improve access and waiting times for patients.

A Further Faster handbook for dermatology has been produced, to share best practice and support National Health Service dermatology teams to reduce the number of Did Not Attend appointments, reduce unnecessary follow ups and, where appropriate, reduce the number of outpatient appointments by booking patients straight to tests, helping to free up capacity for patients in need of specialist dermatology services.

Specifically on atopic dermatitis, and the prescribing of appropriate emollients, the relevant doctor or healthcare professional is responsible for working with their patient and deciding on the best course of treatment. Prescribers take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards when making decisions. The National Institute for Health and Care Excellence (NICE) also publishes a range of guidance on atopic dermatitis and other skin conditions for commissioners and healthcare professionals, with recommendations for diagnosis and referral, which are available at the NICE website.

On dermatology care in general, waiting times, and the proposal for a national service framework, I refer the Noble Baroness to the answer that I provided her on 13 January in response to Question HL13259, which, for ease of reference, is reproduced below:

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. The Government will consider clinical specialities for future waves of modern service frameworks, including allergy, dermatology, which includes chronic spontaneous urticaria (CSU), and immunology. The criteria for determining other conditions for future modern service frameworks will be based on disease burden, care variation, economic impact, and where there is potential for rapid and significant improvements in the quality of care and productivity.

The Department recognises the potential benefits of virtual clinics in improving access to specialist care for conditions like CSU. A central part of our 10-Year Health Plan is moving care closer to home, and we recognise that we need to do this while retaining access to specialist support. Trusts should provide the infrastructure and resources to facilitate virtual consultations, but this should not replace face-to-face care where it is more appropriate, dependent on clinical need, or preferred by individual patients.

NHS England’s service specification for specialised dermatology services for adults and children is designed to reduce regional disparities in care for CSU by setting consistent national standards for diagnosis, treatment, and follow-up. The specification ensures that all patients, regardless of location, have access to evidence-based interventions and specialist expertise, including advanced therapies where clinically appropriate. The specification addresses historical variations in service provision and supports equitable access across integrated care systems. This approach helps to improve outcomes for patients with CSU and ensures a more uniform level of care throughout England.

Additionally, NHS England’s Getting It Right First Time programme is working to improve capacity and waiting times through its established Further Faster programme. This programme brings together hospital trust clinicians and operational teams with the challenge of collectively going ‘further and faster’ to transform patient pathways, reduce unnecessary follow-up outpatient appointments, and improve access and waiting times for patients.

A Further Faster handbook for dermatology has been produced, to share best practice and support National Health Service dermatology teams to reduce the number of Did Not Attend appointments, reduce unnecessary follow ups and, where appropriate, reduce the number of outpatient appointments by booking patients straight to tests, helping to free up capacity for patients in need of specialist dermatology services.

Specifically on atopic dermatitis, and the prescribing of appropriate emollients, the relevant doctor or healthcare professional is responsible for working with their patient and deciding on the best course of treatment. Prescribers take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards when making decisions. The National Institute for Health and Care Excellence (NICE) also publishes a range of guidance on atopic dermatitis and other skin conditions for commissioners and healthcare professionals, with recommendations for diagnosis and referral, which are available at the NICE website.

On dermatology care in general, waiting times, and the proposal for a national service framework, I refer the Noble Baroness to the answer that I provided her on 13 January in response to Question HL13259, which, for ease of reference, is reproduced below:

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. The Government will consider clinical specialities for future waves of modern service frameworks, including allergy, dermatology, which includes chronic spontaneous urticaria (CSU), and immunology. The criteria for determining other conditions for future modern service frameworks will be based on disease burden, care variation, economic impact, and where there is potential for rapid and significant improvements in the quality of care and productivity.

The Department recognises the potential benefits of virtual clinics in improving access to specialist care for conditions like CSU. A central part of our 10-Year Health Plan is moving care closer to home, and we recognise that we need to do this while retaining access to specialist support. Trusts should provide the infrastructure and resources to facilitate virtual consultations, but this should not replace face-to-face care where it is more appropriate, dependent on clinical need, or preferred by individual patients.

NHS England’s service specification for specialised dermatology services for adults and children is designed to reduce regional disparities in care for CSU by setting consistent national standards for diagnosis, treatment, and follow-up. The specification ensures that all patients, regardless of location, have access to evidence-based interventions and specialist expertise, including advanced therapies where clinically appropriate. The specification addresses historical variations in service provision and supports equitable access across integrated care systems. This approach helps to improve outcomes for patients with CSU and ensures a more uniform level of care throughout England.

Additionally, NHS England’s Getting It Right First Time programme is working to improve capacity and waiting times through its established Further Faster programme. This programme brings together hospital trust clinicians and operational teams with the challenge of collectively going ‘further and faster’ to transform patient pathways, reduce unnecessary follow-up outpatient appointments, and improve access and waiting times for patients.

A Further Faster handbook for dermatology has been produced, to share best practice and support National Health Service dermatology teams to reduce the number of Did Not Attend appointments, reduce unnecessary follow ups and, where appropriate, reduce the number of outpatient appointments by booking patients straight to tests, helping to free up capacity for patients in need of specialist dermatology services.

Specifically on atopic dermatitis, and the prescribing of appropriate emollients, the relevant doctor or healthcare professional is responsible for working with their patient and deciding on the best course of treatment. Prescribers take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards when making decisions. The National Institute for Health and Care Excellence (NICE) also publishes a range of guidance on atopic dermatitis and other skin conditions for commissioners and healthcare professionals, with recommendations for diagnosis and referral, which are available at the NICE website.

On dermatology care in general, waiting times, and the proposal for a national service framework, I refer the Noble Baroness to the answer that I provided her on 13 January in response to Question HL13259, which, for ease of reference, is reproduced below:

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. The Government will consider clinical specialities for future waves of modern service frameworks, including allergy, dermatology, which includes chronic spontaneous urticaria (CSU), and immunology. The criteria for determining other conditions for future modern service frameworks will be based on disease burden, care variation, economic impact, and where there is potential for rapid and significant improvements in the quality of care and productivity.

The Department recognises the potential benefits of virtual clinics in improving access to specialist care for conditions like CSU. A central part of our 10-Year Health Plan is moving care closer to home, and we recognise that we need to do this while retaining access to specialist support. Trusts should provide the infrastructure and resources to facilitate virtual consultations, but this should not replace face-to-face care where it is more appropriate, dependent on clinical need, or preferred by individual patients.

NHS England’s service specification for specialised dermatology services for adults and children is designed to reduce regional disparities in care for CSU by setting consistent national standards for diagnosis, treatment, and follow-up. The specification ensures that all patients, regardless of location, have access to evidence-based interventions and specialist expertise, including advanced therapies where clinically appropriate. The specification addresses historical variations in service provision and supports equitable access across integrated care systems. This approach helps to improve outcomes for patients with CSU and ensures a more uniform level of care throughout England.

Additionally, NHS England’s Getting It Right First Time programme is working to improve capacity and waiting times through its established Further Faster programme. This programme brings together hospital trust clinicians and operational teams with the challenge of collectively going ‘further and faster’ to transform patient pathways, reduce unnecessary follow-up outpatient appointments, and improve access and waiting times for patients.

A Further Faster handbook for dermatology has been produced, to share best practice and support National Health Service dermatology teams to reduce the number of Did Not Attend appointments, reduce unnecessary follow ups and, where appropriate, reduce the number of outpatient appointments by booking patients straight to tests, helping to free up capacity for patients in need of specialist dermatology services.

Specifically on atopic dermatitis, and the prescribing of appropriate emollients, the relevant doctor or healthcare professional is responsible for working with their patient and deciding on the best course of treatment. Prescribers take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards when making decisions. The National Institute for Health and Care Excellence (NICE) also publishes a range of guidance on atopic dermatitis and other skin conditions for commissioners and healthcare professionals, with recommendations for diagnosis and referral, which are available at the NICE website.

On dermatology care in general, waiting times, and the proposal for a national service framework, I refer the Noble Baroness to the answer that I provided her on 13 January in response to Question HL13259, which, for ease of reference, is reproduced below:

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. The Government will consider clinical specialities for future waves of modern service frameworks, including allergy, dermatology, which includes chronic spontaneous urticaria (CSU), and immunology. The criteria for determining other conditions for future modern service frameworks will be based on disease burden, care variation, economic impact, and where there is potential for rapid and significant improvements in the quality of care and productivity.

The Department recognises the potential benefits of virtual clinics in improving access to specialist care for conditions like CSU. A central part of our 10-Year Health Plan is moving care closer to home, and we recognise that we need to do this while retaining access to specialist support. Trusts should provide the infrastructure and resources to facilitate virtual consultations, but this should not replace face-to-face care where it is more appropriate, dependent on clinical need, or preferred by individual patients.

NHS England’s service specification for specialised dermatology services for adults and children is designed to reduce regional disparities in care for CSU by setting consistent national standards for diagnosis, treatment, and follow-up. The specification ensures that all patients, regardless of location, have access to evidence-based interventions and specialist expertise, including advanced therapies where clinically appropriate. The specification addresses historical variations in service provision and supports equitable access across integrated care systems. This approach helps to improve outcomes for patients with CSU and ensures a more uniform level of care throughout England.

Additionally, NHS England’s Getting It Right First Time programme is working to improve capacity and waiting times through its established Further Faster programme. This programme brings together hospital trust clinicians and operational teams with the challenge of collectively going ‘further and faster’ to transform patient pathways, reduce unnecessary follow-up outpatient appointments, and improve access and waiting times for patients.

A Further Faster handbook for dermatology has been produced, to share best practice and support National Health Service dermatology teams to reduce the number of Did Not Attend appointments, reduce unnecessary follow ups and, where appropriate, reduce the number of outpatient appointments by booking patients straight to tests, helping to free up capacity for patients in need of specialist dermatology services.

Specifically on atopic dermatitis, and the prescribing of appropriate emollients, the relevant doctor or healthcare professional is responsible for working with their patient and deciding on the best course of treatment. Prescribers take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards when making decisions. The National Institute for Health and Care Excellence (NICE) also publishes a range of guidance on atopic dermatitis and other skin conditions for commissioners and healthcare professionals, with recommendations for diagnosis and referral, which are available at the NICE website.

On dermatology care in general, waiting times, and the proposal for a national service framework, I refer the Noble Baroness to the answer that I provided her on 13 January in response to Question HL13259, which, for ease of reference, is reproduced below:

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. The Government will consider clinical specialities for future waves of modern service frameworks, including allergy, dermatology, which includes chronic spontaneous urticaria (CSU), and immunology. The criteria for determining other conditions for future modern service frameworks will be based on disease burden, care variation, economic impact, and where there is potential for rapid and significant improvements in the quality of care and productivity.

The Department recognises the potential benefits of virtual clinics in improving access to specialist care for conditions like CSU. A central part of our 10-Year Health Plan is moving care closer to home, and we recognise that we need to do this while retaining access to specialist support. Trusts should provide the infrastructure and resources to facilitate virtual consultations, but this should not replace face-to-face care where it is more appropriate, dependent on clinical need, or preferred by individual patients.

NHS England’s service specification for specialised dermatology services for adults and children is designed to reduce regional disparities in care for CSU by setting consistent national standards for diagnosis, treatment, and follow-up. The specification ensures that all patients, regardless of location, have access to evidence-based interventions and specialist expertise, including advanced therapies where clinically appropriate. The specification addresses historical variations in service provision and supports equitable access across integrated care systems. This approach helps to improve outcomes for patients with CSU and ensures a more uniform level of care throughout England.

Additionally, NHS England’s Getting It Right First Time programme is working to improve capacity and waiting times through its established Further Faster programme. This programme brings together hospital trust clinicians and operational teams with the challenge of collectively going ‘further and faster’ to transform patient pathways, reduce unnecessary follow-up outpatient appointments, and improve access and waiting times for patients.

A Further Faster handbook for dermatology has been produced, to share best practice and support National Health Service dermatology teams to reduce the number of Did Not Attend appointments, reduce unnecessary follow ups and, where appropriate, reduce the number of outpatient appointments by booking patients straight to tests, helping to free up capacity for patients in need of specialist dermatology services.

The Government takes seriously the potential risks from increasingly capable AI systems, including the possibility of systems behaving in unintended or unforeseen ways. Our priority is to ensure that the British people are protected as these technologies develop.We will follow the evidence and take whatever proportionate action is necessary where serious risks emerge.

The UK works with bilateral and multilateral partners to advance secure, trustworthy, and responsible AI across countries, built on a shared understanding of capabilities and risks, including through the International AI Safety Report and the International Network for Advanced AI Measurement, Evaluation and Science, which the UK is currently Coordinator of and which met recently in Seoul to discuss best practice in AI evaluations.

The Government takes seriously the potential risks from increasingly capable AI systems, including the possibility of systems behaving in unintended or unforeseen ways. Our priority is to ensure that the British people are protected as these technologies develop.We will follow the evidence and take whatever proportionate action is necessary where serious risks emerge.

The UK works with bilateral and multilateral partners to advance secure, trustworthy, and responsible AI across countries, built on a shared understanding of capabilities and risks, including through the International AI Safety Report and the International Network for Advanced AI Measurement, Evaluation and Science, which the UK is currently Coordinator of and which met recently in Seoul to discuss best practice in AI evaluations.

The Government apologises to passengers across the United Kingdom who faced significant disruption as a result of the issues that impacted NATS’ operation on 8 September, resulting in delays and cancellations for a large number of passengers, as well as the disruption that it has caused for industry. Let us be clear that disruption of this kind is absolutely unacceptable.

Department for Transport officials worked closely with NATS, airports and airlines throughout the incident and recovery period to monitor impacts and provide support where necessary. The Department also provided night flight alleviations, where required, to assist airports in recovering operations.

The Secretary of State asked NATS to provide a report by Wednesday 16 September setting out the cause of the incident and the actions taken in response and has also asked the CAA to conduct an independent review into this matter immediately. The Department will continue to work closely with NATS and the Civil Aviation Authority to ensure the root cause is fully understood, lessons are identified, and appropriate steps are taken to minimise the risk of similar disruption occurring in future.

The Government keeps all tax policy under review and any changes are set out at fiscal events.

Council Tax is a vital source of income for Local Authorities, which the OBR forecasts to raise c. £50.9 billion across England in 2025-26. It ensures households contribute to the cost of local services, including those who rent.

The Government is committed to creating a fairer business rates system over the course of this Parliament that protects the high street, supports investment, and is fit for the 21st century.

The Call for Evidence on business rates and investment, published at Budget 2025, built on the findings of the Transforming Business Rates Discussion Paper and asked stakeholders for more detailed evidence on how the business rates system influences investment decisions. The Government are carefully considering representations received, and a Government response to the Call for Evidence will be published in due course.

The government works closely with local government to identify the capacity implications of devolved powers. This includes the Overnight Visitor Levy where Strategic Authorities will be the tax authority responsible for the administration of the levy. Government will work closely with Strategic Authorities interested in using the power and will assess any financial implications in due course.

At the Local Government Finance Settlement, we confirmed a total of £99.6m of funding over the Spending Review period to support existing eligible Strategic Authorities’ staffing and administrative costs, and central corporate functions. Government will also set out further detail on support for MSA capacity and capability later this year building on the Rewiring the State Cabinet statement.

No formal assessment has been made. The next consultation on NHS England’s Commercial Framework, currently planned for 2026/27, will seek views on commercial options including indication-specific pricing.

No formal assessment has been made. The next consultation on NHS England’s Commercial Framework, currently planned for 2026/27, will seek views on commercial options including indication-specific pricing.

The requested information is not centrally held by the Department and could only be obtained for the purposes of answering this question at disproportionate cost.

The UK has led the way on international tax reforms to ensure that large multinational enterprises pay their fair share of tax on profits arising from their UK activities. This includes fully implementing the actions agreed through the OECD/G20 Base Erosion and Profit Shifting project, and being at the forefront of development and implementation of the Global Minimum Corporate Tax. These reforms have strengthened the international tax framework and reduced opportunities for multinational groups to shift profits artificially. The UK already requires multinational groups to provide country-by-country reports to HMRC, publishes aggregated country-level data, has public reporting requirements in certain sectors and robust wider reporting requirements. The Government believes that any action on public country-by-country reporting should be coordinated internationally to ensure a consistent and comprehensive approach and to minimise the risk of competitive distortions.

Non-domestic rates are already devolved to the Northern Ireland Assembly by the Rates (Northern Ireland) Order 1977.

Local authorities are central to the Government's ambitions for economic growth, public service reform and stronger communities.

As set out in the Government's Rewiring the State Cabinet Statement (here), we are committed to shifting power from central government to local leaders and communities, including through ensuring that powers, functions and resources are exercised at the level most appropriate to achieving better outcomes for people and places.

The Government has also committed to increasing the proportion of business rates retained by local government. Further detail on our approach to devolution and the distribution of responsibilities across different levels of government will be set out in a forthcoming White Paper.

Strategic Institutional Research Funding (SIRF) Review remains ongoing. As outlined in the UKRI Strategy, the review is assessing the effectiveness of Research England’s block grant funding and allocation mechanisms. Any resulting changes to SIRF allocations will be implemented by the end of the Spending Review period.

Rather than a final publication, outputs will be published as they are finalised. Research England plans to publish the Transparency Programme pilot findings, the SIRF Impact Evaluation and the Condition of the Research Estate reports by December 2026 and will continue to work with stakeholders on future elements including a SIRF evaluation report.

The UK, Australia and Canada have each committed £1 million to launch the International Peace Fund. Once operational, the Fund will seek to bring on other donors and scale up efforts. The Fund will complement diplomatic and humanitarian efforts by investing in the social and civic foundations needed for a sustainable peace and by working with partners to mobilise wider international support. We have been clear that a negotiated two-state solution is the only viable route to a just and lasting peace for both Israelis and Palestinians alike.